233 related articles for article (PubMed ID: 27681560)
1. Characterization and phosphoproteomic analysis of a human immortalized podocyte model of Fabry disease generated using CRISPR/Cas9 technology.
Pereira EM; Labilloy A; Eshbach ML; Roy A; Subramanya AR; Monte S; Labilloy G; Weisz OA
Am J Physiol Renal Physiol; 2016 Nov; 311(5):F1015-F1024. PubMed ID: 27681560
[TBL] [Abstract][Full Text] [Related]
2. Enzyme Replacement Therapy Clears Gb3 Deposits from a Podocyte Cell Culture Model of Fabry Disease but Fails to Restore Altered Cellular Signaling.
Braun F; Blomberg L; Brodesser S; Liebau MC; Schermer B; Benzing T; Kurschat CE
Cell Physiol Biochem; 2019; 52(5):1139-1150. PubMed ID: 30990584
[TBL] [Abstract][Full Text] [Related]
3. α-Galactosidase a Deficiency in Fabry Disease Leads to Extensive Dysregulated Cellular Signaling Pathways in Human Podocytes.
Jehn U; Bayraktar S; Pollmann S; Van Marck V; Weide T; Pavenstädt H; Brand E; Lenders M
Int J Mol Sci; 2021 Oct; 22(21):. PubMed ID: 34768768
[TBL] [Abstract][Full Text] [Related]
4. Accumulation of α-synuclein mediates podocyte injury in Fabry nephropathy.
Braun F; Abed A; Sellung D; Rogg M; Woidy M; Eikrem O; Wanner N; Gambardella J; Laufer SD; Haas F; Wong MN; Dumoulin B; Rischke P; Mühlig A; Sachs W; von Cossel K; Schulz K; Muschol N; Gersting SW; Muntau AC; Kretz O; Hahn O; Rinschen MM; Mauer M; Bork T; Grahammer F; Liang W; Eierhoff T; Römer W; Hansen A; Meyer-Schwesinger C; Iaccarino G; Tøndel C; Marti HP; Najafian B; Puelles VG; Schell C; Huber TB
J Clin Invest; 2023 Jun; 133(11):. PubMed ID: 37014703
[TBL] [Abstract][Full Text] [Related]
5. Cardiac manifestations of Fabry disease in G3Stg/GlaKO and GlaKO mouse models-Translation to Fabry disease patients.
Kugadas A; Artoni P; Ruangsiriluk W; Zhao M; Boukharov N; Islam R; Volfson D; Derakhchan K
PLoS One; 2024; 19(5):e0304415. PubMed ID: 38820517
[TBL] [Abstract][Full Text] [Related]
6. Using CRISPR/Cas9-Mediated GLA Gene Knockout as an In Vitro Drug Screening Model for Fabry Disease.
Song HY; Chiang HC; Tseng WL; Wu P; Chien CS; Leu HB; Yang YP; Wang ML; Jong YJ; Chen CH; Yu WC; Chiou SH
Int J Mol Sci; 2016 Dec; 17(12):. PubMed ID: 27983599
[TBL] [Abstract][Full Text] [Related]
7. Enhanced thrombospondin-1 causes dysfunction of vascular endothelial cells derived from Fabry disease-induced pluripotent stem cells.
Do HS; Park SW; Im I; Seo D; Yoo HW; Go H; Kim YH; Koh GY; Lee BH; Han YM
EBioMedicine; 2020 Feb; 52():102633. PubMed ID: 31981984
[TBL] [Abstract][Full Text] [Related]
8. α-Galactosidase A knockout mice: progressive organ pathology resembles the type 2 later-onset phenotype of Fabry disease.
Bangari DS; Ashe KM; Desnick RJ; Maloney C; Lydon J; Piepenhagen P; Budman E; Leonard JP; Cheng SH; Marshall J; Thurberg BL
Am J Pathol; 2015 Mar; 185(3):651-65. PubMed ID: 25553976
[TBL] [Abstract][Full Text] [Related]
9. Human kidney organoids reveal the role of glutathione in Fabry disease.
Kim JW; Kim HW; Nam SA; Lee JY; Cho HJ; Kim TM; Kim YK
Exp Mol Med; 2021 Oct; 53(10):1580-1591. PubMed ID: 34654880
[TBL] [Abstract][Full Text] [Related]
10. Generation of a GLA knock-out human-induced pluripotent stem cell line, KSBCi002-A-1, using CRISPR/Cas9.
Kim YK; Yu JH; Min SH; Park SW
Stem Cell Res; 2020 Jan; 42():101676. PubMed ID: 31841972
[TBL] [Abstract][Full Text] [Related]
11. Altered dynamics of a lipid raft associated protein in a kidney model of Fabry disease.
Labilloy A; Youker RT; Bruns JR; Kukic I; Kiselyov K; Halfter W; Finegold D; do Monte SJ; Weisz OA
Mol Genet Metab; 2014 Feb; 111(2):184-92. PubMed ID: 24215843
[TBL] [Abstract][Full Text] [Related]
12. The kidney in Fabry's disease.
Pisani A; Visciano B; Imbriaco M; Di Nuzzi A; Mancini A; Marchetiello C; Riccio E
Clin Genet; 2014 Oct; 86(4):301-9. PubMed ID: 24645664
[TBL] [Abstract][Full Text] [Related]
13. Functional and Clinical Consequences of Novel α-Galactosidase A Mutations in Fabry Disease.
Lukas J; Scalia S; Eichler S; Pockrandt AM; Dehn N; Cozma C; Giese AK; Rolfs A
Hum Mutat; 2016 Jan; 37(1):43-51. PubMed ID: 26415523
[TBL] [Abstract][Full Text] [Related]
14. Substrate-specific gene expression profiles in different kidney cell types are associated with Fabry disease.
Shin YJ; Jeon YJ; Jung N; Park JW; Park HY; Jung SC
Mol Med Rep; 2015 Oct; 12(4):5049-57. PubMed ID: 26135632
[TBL] [Abstract][Full Text] [Related]
15. ZFN-mediated in vivo gene editing in hepatocytes leads to supraphysiologic α-Gal A activity and effective substrate reduction in Fabry mice.
Pagant S; Huston MW; Moreira L; Gan L; St Martin S; Sproul S; Holmes MC; Meyer K; Wechsler T; Desnick RJ; Yasuda M
Mol Ther; 2021 Nov; 29(11):3230-3242. PubMed ID: 33775910
[TBL] [Abstract][Full Text] [Related]
16. Therapeutic strategy for Fabry disease by intravenous administration of adeno-associated virus 2 or 9 in α-galactosidase A-deficient mice.
Hayashi Y; Sehara Y; Watano R; Ohba K; Takayanagi Y; Muramatsu K; Sakiyama Y; Mizukami H
J Gene Med; 2023 Dec; 25(12):e3560. PubMed ID: 37392007
[TBL] [Abstract][Full Text] [Related]
17. Generation of a CRISPR/Cas9-corrected-hiPSC line (DDLABi001-A) from Fabry disease (FD)-derived iPSCs having α-galactosidase (GLA) gene mutation (c.803_806del).
Choi JB; Seo D; Do HS; Han YM
Stem Cell Res; 2023 Feb; 66():103001. PubMed ID: 36516658
[TBL] [Abstract][Full Text] [Related]
18. Receptor-mediated endocytosis of α-galactosidase A in human podocytes in Fabry disease.
Prabakaran T; Nielsen R; Larsen JV; Sørensen SS; Feldt-Rasmussen U; Saleem MA; Petersen CM; Verroust PJ; Christensen EI
PLoS One; 2011; 6(9):e25065. PubMed ID: 21949853
[TBL] [Abstract][Full Text] [Related]
19. Globotriaosylsphingosine accumulation and not alpha-galactosidase-A deficiency causes endothelial dysfunction in Fabry disease.
Namdar M; Gebhard C; Studiger R; Shi Y; Mocharla P; Schmied C; Brugada P; Lüscher TF; Camici GG
PLoS One; 2012; 7(4):e36373. PubMed ID: 22558451
[TBL] [Abstract][Full Text] [Related]
20. Renal globotriaosylceramide deposits for Fabry disease linked to uncertain pathogenicity gene variant c.352C>T/p.Arg118Cys: A family study.
Cerón-Rodríguez M; Ramón-García G; Barajas-Colón E; Franco-Álvarez I; Salgado-Loza JL
Mol Genet Genomic Med; 2019 Nov; 7(11):e981. PubMed ID: 31566927
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
